Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 24Terminated 13Unknown 8Recruiting 6Active not recruiting 5Withdrawn 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9venetoclax 7toripalimab 7pembrolizumab 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7irinotecan sucrosofate 6Temozolomide 6Fluorouracil 6tislelizumab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5HMPL-013 5Etoposide 5Dexamethasone 5Cisplatin 5Carboplatin 5Capecitabine 5Biopsy 5sintilimab 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Decitabine × Clear all
NCT07389239 2026-02-20

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

University of Chicago

Phase 1/2 Not yet recruiting
24 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡